来源:[1] BMO 在 Sirius 合作后重申 CRISPR Therapeutics (CRSP)“跑赢大盘”评级 (https://finance.yahoo.com/news/bmo-reaffirms- ...)[2] BMO Capital 重申 CRISPR Therapeutics 股票“跑赢大盘”评级,看好血栓市场潜力 - Investing.com (https://www.investing.com/news/stock-market-n ...)[3] CRISPR Therapeutics 在 Casgevy 销售加速之际推进基因编辑管线 (https://www.fool.com/investing/2025/09/30/cou ...)